Respiratory updates


Respiratory medicine
Cystic fibrosis
Lung cancer
Lung disease


As with other fields, respiratory medicine has seen several significant advancements in recent years. The current status and prospects of certain noteworthy ones are presented.


Edmondson C, Davies JC. . Therapeutic Advances in Chronic Disease. 2016;7:170–83. Available from:

Massie J, Delatycki MB. Cystic Fibrosis Carrier Screening. Paediatric Respiratory Reviews. 2013;14:270–5. Available from:

Goldman LS Andrew I. Goldman-Cecil Medicine. Elsevier - Health Science; 2011.

Lawrence H, Moore T, Usmani O, Hickin S. Respiratory System. 2019.

Cystic Fibrosis Trust. Kalydeco. Available from: drugs/kalydeco

Fajac I, De Boeck K. New horizons for cystic fibrosis treatment. Pharmacology & Therapeutics. 2017;170:205–11. Available from:

Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study . Am J Respir Crit Care Med. 2012;185:645–52. Available from:

Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 Years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med. 2013;187:1219–25. Available from:

Cystic Fibrosis Trust. Orkambi. Available from:

Mahase E. Cystic fibrosis: triple therapy shows promising results. BMJ. 2019;l6347. Available from:

Cystic Fibrosis Trust. Triple combination therapy (Trikafta). Available from:

De Boeck K, Davies JC. Where are we with transformational therapies for patients with cystic fibrosis? Current Opinion in Pharmacology. 2017;34:70–5. Available from:

NHS England. NHS England concludes wide-ranging deal for cystic fibrosis drugs. Available from:

Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer. Chest.2018;154:1416–23. Available from:

Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of Anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65. Available from:

Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl JMed. 2015;373:1627–39. Available from:

Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–33. Available from:

Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919–29. Available from:

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. Available from:

Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor–related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607. Available from:

Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. JCO. 2017;35:709–17. Available from:

Voong KR, Hazell S, Hu C, et al. MA 09.08 Receipt of chest radiation and immune-related pneumonitis in patients with NSCLC treated with Anti-PD-1/PD-L1. Journal of Thoracic Oncology. 2017;12:S1837. Available from:

Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28:iv119–42. Available from:

Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20:57. Available from:

Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076. Available from:

Boehringer Ingelheim. INBUILD® meets primary endpoint– study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases. 2019. Available from:

Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4:e000212. Available from: